Annual EBITDA
-$38.77 M
-$10.10 M-35.24%
December 31, 2023
Summary
- As of February 26, 2025, CLRB annual EBITDA is -$38.77 million, with the most recent change of -$10.10 million (-35.24%) on December 31, 2023.
- During the last 3 years, CLRB annual EBITDA has fallen by -$23.62 million (-155.91%).
- CLRB annual EBITDA is now -1412.56% below its all-time high of -$2.56 million, reached on December 31, 2005.
Performance
CLRB EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$13.26 M
+$378.60 K+2.78%
September 30, 2024
Summary
- As of February 26, 2025, CLRB quarterly EBITDA is -$13.26 million, with the most recent change of +$378.60 thousand (+2.78%) on September 30, 2024.
- Over the past year, CLRB quarterly EBITDA has stayed the same.
- CLRB quarterly EBITDA is now -3655.06% below its all-time high of -$353.10 thousand, reached on March 31, 2005.
Performance
CLRB Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$51.29 M
-$3.89 M-8.20%
September 30, 2024
Summary
- As of February 26, 2025, CLRB TTM EBITDA is -$51.29 million, with the most recent change of -$3.89 million (-8.20%) on September 30, 2024.
- Over the past year, CLRB TTM EBITDA has stayed the same.
- CLRB TTM EBITDA is now -14424.98% below its all-time high of -$353.10 thousand, reached on March 31, 2005.
Performance
CLRB TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CLRB EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -35.2% | 0.0% | 0.0% |
| 3 y3 years | -155.9% | -129.3% | -134.6% |
| 5 y5 years | -235.0% | -237.4% | -265.1% |
CLRB EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -61.7% | at low | -125.3% | +2.8% | -115.9% | at low |
| 5 y | 5-year | -176.0% | at low | -295.6% | +2.8% | -265.1% | at low |
| alltime | all time | -1412.6% | at low | -3655.1% | +2.8% | <-9999.0% | at low |
Cellectar Biosciences EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$13.26 M(-2.8%) | -$51.29 M(+8.2%) |
| Jun 2024 | - | -$13.64 M(+14.5%) | -$47.40 M(+12.8%) |
| Mar 2024 | - | -$11.91 M(-4.5%) | -$42.02 M(+8.4%) |
| Dec 2023 | -$38.77 M(+35.2%) | -$12.48 M(+33.1%) | -$38.77 M(+15.1%) |
| Sep 2023 | - | -$9.37 M(+13.5%) | -$33.67 M(+5.0%) |
| Jun 2023 | - | -$8.26 M(-4.7%) | -$32.09 M(+2.7%) |
| Mar 2023 | - | -$8.66 M(+17.3%) | -$31.23 M(+9.0%) |
| Dec 2022 | -$28.67 M(+19.5%) | -$7.38 M(-5.1%) | -$28.67 M(+5.5%) |
| Sep 2022 | - | -$7.78 M(+5.1%) | -$27.16 M(+7.9%) |
| Jun 2022 | - | -$7.40 M(+21.4%) | -$25.17 M(+5.9%) |
| Mar 2022 | - | -$6.10 M(+3.6%) | -$23.75 M(-0.9%) |
| Dec 2021 | -$23.98 M(+58.3%) | -$5.88 M(+1.7%) | -$23.98 M(+9.7%) |
| Sep 2021 | - | -$5.78 M(-3.5%) | -$21.86 M(+9.6%) |
| Jun 2021 | - | -$5.99 M(-5.3%) | -$19.95 M(+13.7%) |
| Mar 2021 | - | -$6.32 M(+68.0%) | -$17.55 M(+15.8%) |
| Dec 2020 | -$15.15 M(+7.9%) | -$3.76 M(-2.8%) | -$15.15 M(+2.8%) |
| Sep 2020 | - | -$3.87 M(+8.0%) | -$14.74 M(-0.4%) |
| Jun 2020 | - | -$3.59 M(-8.6%) | -$14.79 M(+2.9%) |
| Mar 2020 | - | -$3.92 M(+17.1%) | -$14.37 M(+2.3%) |
| Dec 2019 | -$14.05 M(+21.4%) | -$3.35 M(-14.7%) | -$14.05 M(+9.1%) |
| Sep 2019 | - | -$3.93 M(+24.1%) | -$12.87 M(+7.1%) |
| Jun 2019 | - | -$3.17 M(-12.0%) | -$12.01 M(+2.4%) |
| Mar 2019 | - | -$3.60 M(+65.2%) | -$11.73 M(+1.4%) |
| Dec 2018 | -$11.57 M(-4.0%) | -$2.18 M(-29.1%) | -$11.57 M(-5.4%) |
| Sep 2018 | - | -$3.07 M(+6.4%) | -$12.23 M(-2.4%) |
| Jun 2018 | - | -$2.89 M(-16.0%) | -$12.54 M(-1.8%) |
| Mar 2018 | - | -$3.44 M(+21.1%) | -$12.77 M(+5.9%) |
| Dec 2017 | -$12.05 M(+32.6%) | -$2.84 M(-16.0%) | -$12.05 M(+2.3%) |
| Sep 2017 | - | -$3.38 M(+8.4%) | -$11.78 M(+9.3%) |
| Jun 2017 | - | -$3.12 M(+14.3%) | -$10.78 M(+8.8%) |
| Mar 2017 | - | -$2.73 M(+6.4%) | -$9.91 M(+9.0%) |
| Dec 2016 | -$9.09 M(+11.0%) | -$2.56 M(+7.6%) | -$9.09 M(+10.8%) |
| Sep 2016 | - | -$2.38 M(+6.1%) | -$8.20 M(+6.1%) |
| Jun 2016 | - | -$2.24 M(+17.4%) | -$7.74 M(+1.7%) |
| Mar 2016 | - | -$1.91 M(+14.2%) | -$7.60 M(-7.2%) |
| Dec 2015 | -$8.19 M(-11.9%) | -$1.67 M(-12.5%) | -$8.19 M(-5.7%) |
| Sep 2015 | - | -$1.91 M(-9.4%) | -$8.68 M(-3.0%) |
| Jun 2015 | - | -$2.11 M(-15.5%) | -$8.95 M(-1.5%) |
| Mar 2015 | - | -$2.50 M(+15.4%) | -$9.09 M(-2.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2014 | -$9.30 M(-14.5%) | -$2.16 M(-0.9%) | -$9.30 M(-7.0%) |
| Sep 2014 | - | -$2.18 M(-2.9%) | -$10.00 M(-5.8%) |
| Jun 2014 | - | -$2.25 M(-16.9%) | -$10.62 M(-3.3%) |
| Mar 2014 | - | -$2.71 M(-5.4%) | -$10.99 M(+1.0%) |
| Dec 2013 | -$10.88 M(+31.8%) | -$2.86 M(+2.0%) | -$10.88 M(+8.0%) |
| Sep 2013 | - | -$2.80 M(+7.3%) | -$10.07 M(+9.4%) |
| Jun 2013 | - | -$2.61 M(+0.5%) | -$9.20 M(+5.9%) |
| Mar 2013 | - | -$2.60 M(+26.8%) | -$8.69 M(+4.6%) |
| Dec 2012 | -$8.26 M(+23.7%) | -$2.05 M(+5.9%) | -$8.30 M(-8.7%) |
| Sep 2012 | - | -$1.94 M(-7.9%) | -$9.09 M(+1.9%) |
| Jun 2012 | - | -$2.10 M(-5.1%) | -$8.92 M(+5.8%) |
| Mar 2012 | - | -$2.22 M(-22.0%) | -$8.43 M(+26.3%) |
| Dec 2011 | -$6.67 M(+87.4%) | -$2.84 M(+61.2%) | -$6.67 M(+58.9%) |
| Sep 2011 | - | -$1.76 M(+9.3%) | -$4.20 M(+44.8%) |
| Jun 2011 | - | -$1.61 M(+251.2%) | -$2.90 M(+13.6%) |
| Mar 2011 | - | -$459.00 K(+25.5%) | -$2.55 M(-44.7%) |
| Dec 2010 | -$3.56 M(-64.9%) | -$365.60 K(-21.0%) | -$4.61 M(-41.0%) |
| Sep 2010 | - | -$462.90 K(-63.4%) | -$7.82 M(-19.0%) |
| Jun 2010 | - | -$1.27 M(-49.8%) | -$9.64 M(-7.6%) |
| Mar 2010 | - | -$2.52 M(-29.3%) | -$10.43 M(+2.9%) |
| Dec 2009 | -$10.13 M(-38.9%) | -$3.57 M(+55.7%) | -$10.13 M(+16.3%) |
| Sep 2009 | - | -$2.29 M(+11.6%) | -$8.71 M(-2.9%) |
| Jun 2009 | - | -$2.05 M(-7.6%) | -$8.97 M(-22.9%) |
| Mar 2009 | - | -$2.22 M(+3.7%) | -$11.63 M(-29.8%) |
| Dec 2008 | -$16.57 M(-18.3%) | -$2.14 M(-16.0%) | -$16.57 M(-21.5%) |
| Sep 2008 | - | -$2.55 M(-45.8%) | -$21.12 M(-16.2%) |
| Jun 2008 | - | -$4.71 M(-34.2%) | -$25.21 M(+1.1%) |
| Mar 2008 | - | -$7.16 M(+7.1%) | -$24.93 M(+22.9%) |
| Dec 2007 | -$20.28 M(+127.3%) | -$6.69 M(+0.7%) | -$20.28 M(+23.5%) |
| Sep 2007 | - | -$6.64 M(+49.8%) | -$16.43 M(+28.6%) |
| Jun 2007 | - | -$4.43 M(+76.4%) | -$12.78 M(+27.8%) |
| Mar 2007 | - | -$2.51 M(-11.4%) | -$10.00 M(+12.1%) |
| Dec 2006 | -$8.92 M(+248.0%) | -$2.84 M(-5.2%) | -$8.92 M(+30.7%) |
| Sep 2006 | - | -$2.99 M(+80.6%) | -$6.83 M(+42.4%) |
| Jun 2006 | - | -$1.66 M(+15.7%) | -$4.79 M(+31.6%) |
| Mar 2006 | - | -$1.43 M(+92.4%) | -$3.64 M(+42.1%) |
| Dec 2005 | -$2.56 M | -$744.60 K(-22.4%) | -$2.56 M(+40.9%) |
| Sep 2005 | - | -$959.70 K(+89.7%) | -$1.82 M(+111.7%) |
| Jun 2005 | - | -$506.00 K(+43.3%) | -$859.10 K(+143.3%) |
| Mar 2005 | - | -$353.10 K | -$353.10 K |
FAQ
- What is Cellectar Biosciences annual EBITDA?
- What is the all time high annual EBITDA for Cellectar Biosciences?
- What is Cellectar Biosciences annual EBITDA year-on-year change?
- What is Cellectar Biosciences quarterly EBITDA?
- What is the all time high quarterly EBITDA for Cellectar Biosciences?
- What is Cellectar Biosciences quarterly EBITDA year-on-year change?
- What is Cellectar Biosciences TTM EBITDA?
- What is the all time high TTM EBITDA for Cellectar Biosciences?
- What is Cellectar Biosciences TTM EBITDA year-on-year change?
What is Cellectar Biosciences annual EBITDA?
The current annual EBITDA of CLRB is -$38.77 M
What is the all time high annual EBITDA for Cellectar Biosciences?
Cellectar Biosciences all-time high annual EBITDA is -$2.56 M
What is Cellectar Biosciences annual EBITDA year-on-year change?
Over the past year, CLRB annual EBITDA has changed by -$10.10 M (-35.24%)
What is Cellectar Biosciences quarterly EBITDA?
The current quarterly EBITDA of CLRB is -$13.26 M
What is the all time high quarterly EBITDA for Cellectar Biosciences?
Cellectar Biosciences all-time high quarterly EBITDA is -$353.10 K
What is Cellectar Biosciences quarterly EBITDA year-on-year change?
Over the past year, CLRB quarterly EBITDA has changed by $0.00 (0.00%)
What is Cellectar Biosciences TTM EBITDA?
The current TTM EBITDA of CLRB is -$51.29 M
What is the all time high TTM EBITDA for Cellectar Biosciences?
Cellectar Biosciences all-time high TTM EBITDA is -$353.10 K
What is Cellectar Biosciences TTM EBITDA year-on-year change?
Over the past year, CLRB TTM EBITDA has changed by $0.00 (0.00%)